CapsoVision (CV) Current Deferred Revenue (2024 - 2025)
CapsoVision's (CV) quarterly Current Deferred Revenue came in at $177000.0 in Q4 2025, up 34.09% year-on-year from $132000.0 in Q4 2024, and up 66.98% quarter-over-quarter from $106000.0 in Q3 2025.
CapsoVision (CV) Current Deferred Revenue (2024 - 2025) Analysis & Trends
CapsoVision has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $177000.0 for Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $177000.0, up 34.09% year-over-year; the trailing twelve-month figure through Dec 2025 was $177000.0 (up 34.09% YoY), and the FY2025 annual result was $177000.0, up 34.09% from the prior year.
- Current Deferred Revenue came in at $177000.0 for Q4 2025 at CapsoVision, up from $106000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $177000.0 in Q4 2025 to a low of $97000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | CapsoVision | 176.55 Mn | 166.44 Mn | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 177,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Dec 31, 2024 | 132,000.00 |